ICU Medical (ICUI) as of March 31, 2026 presents a deeply negative liquidation posture consistent with a leveraged post-acquisition balance sheet. Applying standard liquidation haircuts to the reported asset base: cash at 100% yields $288M; accounts receivable (net $201M) at 92% yields ~$185M; inventory ($606M gross) at 60% yields ~$363M; PP&E (net $445M) at 60% yields ~$267M; intangibles ($599M net, exclusive of goodwill) receive zero recovery; goodwill ($1.49B) receives zero recovery; and the equity method investment in the OPF joint venture ($131M carrying value) is uncertain but likely near-zero in a distressed liquidation scenario. Estimated gross liquidation asset recovery: approximately $1.23B to $1.35B depending on assumptions. Against this, face-value liabilities include: total debt carrying value of $1.28B (principal $1.29B less $9M issuance costs, treated at face in liquidation); current liabilities of $518M (including $315M accrued liabilities and $174M payables); long-term lease obligations ($54M operating, $6M finance); operating lease undiscounted commitment of $63M; other noncurrent liabilities of $82M; deferred tax liabilities of $15M; and the $25M noncurrent accrued income taxes. Total claims approximate $2.1B to $2.2B at face, yielding an estimated liquidation deficit to equity of approximately $750M to $950M, broadly consistent with MFFAIS's latest operating liquidation value of -$730M and cash liquidation value of -$1.54B (the wide spread reflects the significant inventory and PP&E haircut sensitivity). The primary drivers of the negative recovery are: (1) $1.49B of goodwill receiving zero recovery — sourced from the 2022 Smiths Medical acquisition; (2) $599M net finite-lived intangibles also zeroed; and (3) $1.29B gross long-term debt principal standing at face value in liquidation. Since the prior annual filing (December 31, 2025), total debt principal is marginally lower ($1.29B vs. $1.29B at year-end, reflecting $4.7M in Q1 2026 scheduled amortization on Term Loan A). Goodwill declined slightly due to $11.4M in foreign currency translation. The operating lease liability stack is unchanged in structure. A pending disposition of certain business assets (deposit of $2.0M received in Q1 2026) is noted in investing activities but is not yet closed and carries no balance sheet impact beyond the deposit. An unresolved 2025 FDA Warning Letter (MedFusion/CADD pumps) carries unquantified contingent liability; no accrual has been established. The field service corrective action reserve stands at $30.7M. The filing does not separately XBRL-tag the deferred tax asset valuation allowance balance as of March 31, 2026; the prior 10-K disclosed a $102.7M allowance at December 31, 2025. A $29.2M tax benefit from expiration of statute of limitations was recognized in Q1 2026, which improves near-term cash position but does not alter the underlying intangible-heavy asset structure relevant to liquidation.
▼ Community Notes